MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Therapeutic Advances in Medical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

84 results · 1 filter active ·
Results by year
20092025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
84 works in the cohort · of 4,299,418page 1 of 2

Labels cover 0 of 84 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 84 of 84 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
An overview of the c-MET signaling pathway
Shawna Organ, Ming‐Sound Tsao
2011· article· en· Therapeutic Advances in Medical Oncology· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
864
citations
fundno affunlabeled
The role of aberrant DNA methylation in cancer initiation and clinical impacts
Franziska Geissler, Ksenija Nesic, Olga Kondrashova, Alexander Dobrovic, Elizabeth M. Swisher, Clare L. Scott +1 more
2024· article· en· Therapeutic Advances in Medical Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
91
citations
affunlabeled
Renal cell carcinoma bone metastases: clinical advances
Chakshu Sahi, Jennifer J. Knox, Mark Clemons, Anthony M. Joshua, Reuben Broom
2010· article· en· Therapeutic Advances in Medical Oncology· Medicine
distilled prediction:candidate · sts+research_integrity+insufficient_payloadconsensus · none
42
citations
affunlabeled
Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer
Abu Shadat Mohammod Noman, Rashed R. Parag, Muhammad Rashid, Mohammad Zeshaan Rahman, Afrin Sultana, Chandsultana Jerin +20 more
2020· article· en· Therapeutic Advances in Medical Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
35
citations
affunlabeled
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy, Massimo Cristofanilli, Stephanie L. Graff, Seock-Ah Im +9 more
2025· article· en· Therapeutic Advances in Medical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
23
citations
affunlabeled
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer
Heather L. McArthur, Sara M. Tolaney, Rebecca Dent, Peter Schmid, Jamil Asselah, Qiang Liu +9 more
2025· article· en· Therapeutic Advances in Medical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
21
citations
affunlabeled
Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
Miguel Burgos, Iván Cavero‐Redondo, Celia Álvarez‐Bueno, Eva María Galán‐Moya, Atanasio Pandiella, Eitan Amir +1 more
2022· article· en· Therapeutic Advances in Medical Oncology· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
21
citations
affunlabeled
Clinical trial reform in the post-COVID era
Meghan E. Mahoney, Srikala S. Sridhar
2023· review· en· Therapeutic Advances in Medical Oncology· Medicine
distilled prediction:candidate · research_integrityconsensus · none
11
citations
aboutno affunlabeled
Exemestane in the prevention setting
Jennifer K. Litton, Therese B. Bevers, Banu Arun
2012· article· en· Therapeutic Advances in Medical Oncology· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
10
citations
next →

How this was built: Screen · Findings · About